The Pathologist
  • Explore Pathology

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Molecular Pathology
    • Infectious Disease
    • Digital Pathology

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Oncology
    • Histology
    • Cytology
    • Hematology
    • Endocrinology
    • Neurology
    • Microbiology & Immunology
    • Forensics
    • Pathologists' Assistants
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways
    • Workforce Trends

    Educational Resources

    • Guidelines & Recommendations
    • App Notes
    • eBooks

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Profiles & Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Pathology Captures
Subscribe
Subscribe

False

The Pathologist / Issues / 2026 / November / The New Front Line of STI Diagnosis
Omics Precision medicine Research and Innovations Molecular Pathology

The New Front Line of STI Diagnosis

Point-of-care and at-home tests are expanding access while creating new challenges for reporting and public health surveillance

By Nikolina Babic, Sheldon Campbell, Kate Crawford 11/18/2026 Discussion 5 min read
  • Full Article
  • Summary
  • Takeaways
  • Listen
  • Scorecard
  • Quiz
  • Poll

Share

Sexually transmitted infections (STIs) have been documented since ancient times and remain a major public health challenge in the United States and worldwide. Common infections such as Chlamydia trachomatis and Neisseria gonorrhoeae are frequently asymptomatic, but untreated cases can lead to infertility, ectopic pregnancy, and an increased risk of HIV transmission.

Conventional testing often requires specimens to be sent to an off-site laboratory, with results returning hours or days later. During that delay, patients may be lost to follow-up or treated empirically, potentially resulting in missed infections, unnecessary antibiotic use, and missed opportunities for public health intervention.

Point-of-care (POC) testing offers an alternative by providing results at or near the site of care, often during the same visit. For clinicians and patients, the goal is straightforward: test, diagnose, and treat in a single encounter.

What is POC testing?

POC tests are diagnostic assays performed outside the traditional clinical laboratory and close to the patient. Results are typically available within minutes to an hour, allowing clinicians to make decisions during the same visit.

Recently introduced POC tests for STIs are FDA-cleared and CLIA-waived, meaning they are designed to be simple to perform and carry a low risk of error when used according to the manufacturer’s instructions.

Kate Crawford

Testing STIs at the POC

POC tests are available for several major STIs, although test types and performance vary by organism.

Rapid antibody and antigen-antibody tests for syphilis and HIV have been used for years in clinical and public health settings. These assays are commonly CLIA-waived, use fingerstick whole blood, and provide results in less than 30 minutes.

Historically, POC tests for C. trachomatis and N. gonorrhoeae had unacceptably low sensitivity. Rapid molecular platforms based on nucleic acid amplification testing have changed this. FDA-cleared, CLIA-waived assays can now detect chlamydia and gonorrhea with accuracy approaching that of laboratory-based testing in approximately 20 minutes. Some newer platforms also test for Mycoplasma genitalium and Trichomonas vaginalis.

POC tests for herpes simplex virus and human papillomavirus are not yet available.

Increased risk populations

STIs do not affect all populations equally. In the United States, the burden is disproportionately concentrated among certain demographic and social groups because of biological factors, social determinants of health, and barriers to care. The Centers for Disease Control and Prevention and other public health agencies identify adolescents and young adults, men who have sex with men, pregnant people, racial and ethnic minority populations, and people with limited access to health care as groups at increased risk.

Many STIs are asymptomatic, particularly during their early stages, contributing to delayed diagnosis and continued transmission. People aged 15–24 account for a disproportionate share of new infections despite representing a smaller proportion of the sexually active population. Biological susceptibility, limited access to confidential care, and lower screening rates all contribute to this increased risk.

Racial and ethnic minority populations are also disproportionately affected. These disparities cannot be explained by individual behavior alone; they are closely associated with structural factors such as limited access to health care, stigma, discrimination, and historical inequalities in public health investment.

Other vulnerable populations include people experiencing homelessness, migrants, and those with unstable housing or insurance coverage. These groups often have a higher prevalence of STIs and are less likely to return for test results, underscoring the importance of accessible testing and reliable follow-up.

Nikolina Babic

Benefits for vulnerable populations

POC testing offers particular benefits for people who face barriers to conventional laboratory-based STI testing. By providing results during the same clinical encounter, it reduces dependence on follow-up visits that may be missed because of transportation difficulties, work commitments, housing instability, or stigma surrounding sexual health care.

Same-day diagnosis allows treatment to begin immediately, which is especially important for patients who may not return for their results. Earlier treatment may reduce transmission and help prevent complications such as pelvic inflammatory disease, infertility, and congenital infection.

Rapid testing may also improve the acceptability and uptake of STI screening. Patients often view it as more convenient, private, and empowering, particularly when offered in community-based or other nontraditional settings. These benefits are especially relevant to adolescents, sexual and gender minorities, and people who may avoid care because of concerns about privacy or judgment.

Accurate rapid testing can also reduce reliance on syndromic treatment, support antimicrobial stewardship, and limit unnecessary antibiotic exposure.

Pathologists and laboratory professionals have an important role in test selection, implementation, quality assurance, and oversight. POC testing does not replace centralized laboratory services, but it can complement them where loss to follow-up is common or rapid treatment is important. With appropriate training, quality controls, and integration into health care systems, STI POC testing may help reduce disparities and strengthen prevention efforts.

Benefits for patients and health systems

The primary advantage of POC testing is the ability to diagnose and treat patients during the same visit, helping to reduce transmission and prevent complications. It may also improve operational efficiency by reducing the need for follow-up calls or additional appointments to communicate results and begin treatment.

Other potential benefits include:

  • Reducing loss to follow-up, particularly among high-risk and underserved populations.

  • Limiting reliance on syndromic management, which may be inaccurate for STIs.

  • Supporting antimicrobial stewardship by avoiding unnecessary empiric treatment.

From a public health perspective, faster diagnosis may also strengthen disease surveillance and outbreak control.

Limitations and challenges

Despite their potential benefits, POC tests are not suitable for every patient or clinical setting. Important limitations include:

  • Cost and operational complexity, particularly for molecular platforms.

  • Restrictions on specimen types, including limited approval for extragenital testing with some assays.

  • The need for quality oversight, because CLIA-waived tests are not error-proof and still require staff training, competency assessment, and quality control.

Workflow, staffing, and testing volume may also make POC implementation impractical in some settings.

Sheldon Campbell

Pathologists role in POC testing

Pathologists and laboratory professionals play a central role in the responsible adoption of POC STI testing. Their responsibilities include:

  • Evaluating analytical performance and clinical suitability.

  • Overseeing quality management and regulatory compliance.

  • Integrating results into laboratory information systems and electronic health records.

  • Advising clinicians on test selection and result interpretation.

Even when testing moves closer to the patient, laboratory oversight remains essential to ensure that results are accurate, reliable, and clinically meaningful.

Looking ahead

Innovation in STI diagnostics is focused on shorter turnaround times, broader organism panels, antimicrobial resistance detection, and lower costs. Organizations such as the World Health Organization continue to encourage the development of POC tests that meet defined performance and usability standards, particularly to support access across diverse care settings.

Self-collection is another developing area, although it is not always considered POC testing. Patients can collect specimens privately at home, reducing the stigma, scheduling difficulties, and discomfort that may discourage screening. These specimens are then mailed to a CLIA-certified laboratory for analysis, with results generally returned within several days. The laboratory remains integral to this model, and established quality oversight and public health reporting requirements continue to apply.

A further change occurred in March 2025, when the FDA granted De Novo marketing authorization for the first nonprescription STI test that can be performed entirely at home. The PCR-based test uses a self-collected vaginal swab and provides results in approximately 30 minutes. A companion app manages test timing, interprets the result, and can connect patients with telehealth services for follow-up care and prescriptions.

The authorization also created a new regulatory classification, establishing a 510(k) pathway for similar devices. This may allow additional over-the-counter molecular STI tests to enter the market. Distribution through same-day delivery services in several US metropolitan areas may further reduce barriers to access.

For pathologists and laboratory professionals, fully at-home molecular testing raises important questions about quality oversight, result reporting, clinical follow-up, and integration with public health surveillance. Collaboration among clinicians, laboratory professionals, regulators, and public health agencies will be essential as these testing models develop.

Newsletters

Receive the latest pathologist news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

About the Author(s)

Nikolina Babic

Nikolina Babic is Board-certified clinical chemist and Professor of Pathology and Laboratory Medicine, Medical University of South Carolina.

More Articles by Nikolina Babic

Sheldon Campbell

Sheldon Campbell is Professor of Laboratory Medicine, Yale School of Medicine, and Director of Clinical Laboratories, VA Connecticut Healthcare System.

More Articles by Sheldon Campbell

Kate Crawford

Kate Crawford is Acting Assistant Professor, Department of Laboratory Medicine and Pathology, University of Washington.

More Articles by Kate Crawford

Explore More in Pathology

Dive deeper into the world of pathology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement

Recommended

False

Affiliations:

Specialties:

Areas of Expertise:

Contributions:

False

The Pathologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Your Privacy Choices
  • Advertise With Us
  • Contact Us

Copyright © 2026 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.